polyICLC
Showing 1 - 13 of 13
Head and Neck Squamous Cell Carcinoma, Breast Cancer, Sarcoma Trial in United States (Durvalumab, Tremelimumab, Poly ICLC)
Completed
- Head and Neck Squamous Cell Carcinoma
- +10 more
- Durvalumab
- +2 more
-
Atlanta, Georgia
- +6 more
Mar 1, 2022
Prostate Cancer Trial in New York (Intratumoral (IT) Poly ICLC 0.5 mg, Intratumoral (IT) Poly ICLC 1.0 mg, Intramuscular (IM)
Completed
- Prostate Cancer
- Intratumoral (IT) Poly ICLC 0.5 mg
- +3 more
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Sep 8, 2022
Melanoma, Metastatic Melanoma, Mucosal Melanoma Trial in Houston, Charlottesville (Peptide Vaccine (LPV7) + Tetanus peptide,
Unknown status
- Melanoma
- +2 more
- Peptide Vaccine (LPV7) + Tetanus peptide
- +3 more
-
Houston, Texas
- +1 more
Nov 15, 2020
Primary Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Philadelphia (OC-L, Montanide, poly-ICLC
Terminated
- Primary Ovarian Cancer
- +2 more
- OC-L
- +2 more
-
Philadelphia, PennsylvaniaOvarian Cancer Research Center
Apr 23, 2020
Glioma, Malignant, Antigen-specific Vaccines, Individualized Treatment Trial in Shanghai (NeoPep Vaccine1 plus Poly-ICLC, NeoPep
Recruiting
- Glioma, Malignant
- +2 more
- NeoPep Vaccine1 plus Poly-ICLC
- NeoPep Vaccine2 plus Poly-ICLC
-
Shanghai, Shanghai, ChinaShanghai 10th People's Hospital
Oct 7, 2022
Allergic Rhinitis, Asthma, Latent Tuberculosis Trial in Paddington (Poly ICLC, Poly I:C, R848)
Completed
- Allergic Rhinitis
- +2 more
- Poly ICLC
- +5 more
-
Paddington, London, United KingdomImperial Clinical Respiratory Research Unit (ICRRU), St Mary's H
Nov 3, 2021
Breast Cancer Trial in Charlottesville (poly-ICLC, 9 Peptides from Her-2/neu, CEA, & CTA, Peptide-tet)
Terminated
- Breast Cancer
- poly-ICLC
- +2 more
-
Charlottesville, VirginiaUniversity of Virginia Health System
May 7, 2020
Melanoma, Head Neck Cancer, Sarcoma Trial in United States (Hiltonol)
Completed
- Melanoma
- +3 more
- Hiltonol
-
Chevy Chase, Maryland
- +4 more
Dec 15, 2020
Acute Myeloid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Buffalo
Completed
- Acute Myeloid Leukemia
- +4 more
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401
- +3 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Jan 16, 2020
Glioblastoma Trial in Worldwide (APVAC1 vaccine plus Poly-ICLC and GM-CSF, APVAC2 vaccine plus Poly-ICLC and GM-CSF)
Completed
- Glioblastoma
- APVAC1 vaccine plus Poly-ICLC and GM-CSF
- APVAC2 vaccine plus Poly-ICLC and GM-CSF
-
Copenhagen, Denmark
- +5 more
Aug 6, 2018
Melanoma Trial in Charlottesville (pBCAR3-phosphopeptide, pIRS2-phosphopeptide, 2-MpP (pBCAR3-phosphopeptide +
Completed
- Melanoma
- pBCAR3-phosphopeptide
- +2 more
-
Charlottesville, VirginiaUniversity of Virginia
Aug 11, 2016
Melanoma Trial in Charlottesville (MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS), MELITAC 12.1 + Montanide ISA-51 +
Completed
- Melanoma
- MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS)
- MELITAC 12.1 + Montanide ISA-51 + polyICLC
-
Charlottesville, VirginiaUniversity of Virginia
Aug 11, 2016
HIV-1 Infected Adults With Chronic HIV-1 Infection Trial in New York (Arm A: Poly-ICLC, Arm B: Normal Saline)
Completed
- HIV-1 Infected Adults With Chronic HIV-1 Infection
- Arm A: Poly-ICLC
- Arm B: Normal Saline
-
New York, New YorkThe Rockefeller University Hospital
Feb 13, 2018